FDA clears second Remicade biosimilarIn what is expected to produce hefty saving for rheumatoid arthritis patients and the healthcare system, FDA approved the second biosimilar to Remicade (Johnson & Johnson). Potential blockbuster arthritis drug delayedCiting safety concerns, FDA delayed approval of a new blockbuster drug to treat rheumatoid arthritis. New strategies for managing drug spend: RA, Cancer, Hep C March 04, 2017By Mari EdlinThe proliferation of specialty drugs has prompted new techniques for keeping costs in tow. Six diseases reap benefits of biomarkers, genetic tests March 02, 2017By Karen AppoldBiomarker testing for harmful genetic mutations provides the opportunity to identify at-risk individuals who might benefit from risk modification strategies and/or enhanced disease screening. Protocols for High-Risk Pregnancies: Autoimmune Disease February 01, 2017By Judith M. Orvos ELSIn this protocol, Dr Lockwood reviews the pathophysiology, diagnosis, and management of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA). Will new autoimmune drugs address cost concerns? December 27, 2016By Erin Bastick PharmDFind out what’s in the drug pipeline for autoimmune disease. Integrating pharmacy benefit, medical benefit cuts costs November 29, 2016By Tracey WalkerHere’s how one non-profit health plan harnessed the power of medical and pharmacy data to rein in drug costs. Rheumatoid arthritis: Partnering for optimal care
October 10, 2016The goal of this activity is to educate pharmacists and technicians in how best to assist patients in the use of medications used to treat rheumatoid arthritis.
Will docs prescribe the new RA biosimilars? October 07, 2016By Christine BlankWhile FDA recently approved two new biosimilars for rheumatoid arthritis and other inflammatory diseases, questions remain about how quickly physicians and patients will embrace the new drugs.